Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 11/02/22 | 8-K | Current report filing |
|
   |
11 |
| 11/01/22 | 8-K | Current report filing |
|
|
3 |
| 10/31/22 | 8-K | Current report filing |
|
|
3 |
| 10/17/22 | 8-K | Current report filing |
|
|
2 |
| 10/04/22 | 3 | Initial statement of beneficial ownership of securities |
|
2 | |
| 10/04/22 | 8-K | Current report filing |
|
|
3 |
| 09/29/22 | 8-K | Current report filing |
|
|
3 |
| 09/21/22 | 8-K | Current report filing |
|
|
2 |
| 09/19/22 | 424B4 | Prospectus filed pursuant to Rule 424(b)(4) |
|
9 | |
| 09/19/22 | 8-K | Current report filing |
|
|
3 |
